Monday, 6 March 2017

CID Weekly Seminar Series: Presented by Dr Sarah Jones and Dr Poh-Yi Gan, 7 March

Tuesday 7 March, 12:00 - 12:30pm, Seminar Room 1, TRF Building

New directions in GILZ research: shining a light on an important new target for treatment of autoimmune diseases
Dr Sarah Jones
Research Fellow, Centre for Inflammatory Diseases

For years our group has sought to identify and characterise a safer alternative to glucocorticoids (“steroids”) for treatment of patients with autoimmune diseases, particularly systemic lupus erythematosus (SLE). GILZ has emerged as a strong candidate, with important roles in regulating activation and effector function in multiple types of immune cells that contribute to disease pathogenesis. I will highlight some new directions for our research, and steps we are taking on the pathway to clinical translation of our work. 

Expanding endogenous antigen specific T regulatory cells as therapy in autoimmune anti-MPO GN
Dr Poh-Yi Gan
Research Fellow, Centre for Inflammatory Diseases

Myeloperoxidase anti-neutrophil cytoplasmic antigen associated glomerulonephritis (MPO-ANCA GN) is a major cause of renal failure. Despite current therapies, this disease has considerable therapeutic toxicities and a 30% mortality at five years. This disease has been shown to result from autoimmunity to MPO in neutrophil lysosomes. Recent advances in the biological manipulation of autoimmunity by induction of therapeutic regulatory T cells (Tregs) offers more specific, safer, alternative therapies. An emerging strategy for enhancing immunomoulation to autoantigens after the development of autoimmunity has been to re-present the autoantigenic immunodominant peptides into physiological homeostatic pathways of apoptotic cell clearance.

A light lunch is served prior to the seminar at 11:45am in the seminar room foyer, level 2, TRF Building.
Further information, including the link to add the seminar series to your google calendar, is available from CID Weekly Seminar Series website []

No comments:

Post a Comment